Blueprint Medicines Corporation (BPMC)

107,00 +12,14 (+12,80%) Börsenschluss: 04:00PM EDT

Blueprint Medicines Corporation

45 Sidney Street
Cambridge, MA 02139
United States
617 374 7580
https://www.blueprintmedicines.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 655

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Kathryn Haviland	President, CEO & Director	1,52M	N/A	1976
Mr. Alexis A. Borisy A.M.	Co-Founder & Director	50k	N/A	1972
Mr. Michael Landsittel	Chief Financial Officer	881,86k	N/A	1972
Ms. Christina Rossi M.B.A.	Chief Operating Officer	1,1M	N/A	1976
Dr. Fouad Namouni M.D.	President of Research & Development	1,1M	N/A	1969
Ms. Ariel Hurley	Senior VP, Finance & Principal Accounting Officer	N/A	N/A	1974
Dr. Christopher K. Murray Ph.D.	Chief Technical Operations & Quality Officer	338,37k	N/A	1963
Ms. Debra Durso-Bumpus	Chief People Officer	N/A	N/A	1970
Mr. Julian Charles Baker	Senior Vice President of Corporate Affairs	N/A	N/A	1967
Dr. Becker Hewes M.D.	Chief Medical Officer	N/A	N/A	1966

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Blueprint Medicines Corporations ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 2, Vorstand: 8, Shareholderrechte: 7, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.